4-hydroxycyclophosphamide has been researched along with Breast Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Harahap, Y; Hasanah, YIF; Purwanto, DJ | 1 |
| Burns, K; Findlay, M; Helsby, N; Porter, D; Yong, M | 1 |
| Michelin, OC; Paiva, BS; Paiva, CE | 1 |
| Afsar, NA; Ahmad, HR; Ahmed, KZ; Cascorbi, I; Haenisch, S; Mateen, A; Remmler, C; Ufer, M; Usman, A | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; van Dam, SM | 1 |
| Ebi, H; Fujiki, Y; Itoh, K; Kanada, Y; Komagata, S; Minami, H; Mukai, H; Nakajima, M; Yokoi, T | 1 |
| Beijnen, JH; Doodeman, VD; Ekhart, C; Huitema, AD; Rodenhuis, S; Smits, PH | 1 |
| Bielenstein, M; Johansson, M | 1 |
| Anasetti, C; Appelbaum, FR; Bensinger, WI; Buckner, CD; Kalhorn, TF; Lambert, K; McDonald, GB; Slattery, JT | 1 |
| Bergh, J; Fjällskog, ML; Freijs, A; Karlsson, MO; Larsson, R; Nygren, P; Sandström, M | 1 |
| Anderson, LW; Black, KC; Chen, TL; Colvin, OM; Grochow, LB; Kennedy, MJ; Kiraly, SB | 1 |
| Anderson, LW; Chen, TL; Collins, JM; Colvin, OM; Grochow, LB; Kennedy, MJ; Strong, JM | 1 |
| Abdel-Rehim, M; Bielenstein, M; Björkstrand, B; Hassan, M; Johansson, M; Karlsson, MO; Ljungman, P; Nilsson, C; Olsson, H; Svensson, US | 1 |
| Ara, G; Bunnell, C; Elias, A; Frei, E; Richardson, P; Teicher, B; Tew, K; Wheeler, C | 1 |
| Armstrong, DK; Chen, TL; Davidson, NE; Goodman, SN; Grochow, L; Hahm, HA; Kennedy, MJ; Passos-Coelho, J | 1 |
| Bornstein, R; Fruehauf, JP; Li, KT; McLaren, CE; Mehta, RS; Nguyen, KP; Parker, RJ; Yu, IR | 1 |
| Kovacs, E | 1 |
6 trial(s) available for 4-hydroxycyclophosphamide and Breast Neoplasms
| Article | Year |
|---|---|
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Female; Genotype; Humans; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Young Adult | 2021 |
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 Enzyme System; Doxorubicin; Female; Fluorouracil; Genotype; Glutathione Transferase; Humans; Leukocyte Count; Middle Aged | 2012 |
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Phosphoramide Mustards; Prodrugs; Thiotepa; Time Factors; Triethylenephosphoramide | 2005 |
Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.
Topics: Adult; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Interactions; Female; Half-Life; Humans; Infusions, Intravenous; Leukemia; Male; Metabolic Clearance Rate; Middle Aged | 1996 |
Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Microsomes, Liver; Middle Aged; Phosphoramide Mustards; Thiotepa | 1996 |
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
Topics: Adult; Antineoplastic Agents, Alkylating; Biotransformation; Breast Neoplasms; Cyclophosphamide; Female; Half-Life; Humans; Middle Aged; Models, Biological | 1999 |
12 other study(ies) available for 4-hydroxycyclophosphamide and Breast Neoplasms
| Article | Year |
|---|---|
Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Dried Blood Spot Testing; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Middle Aged; Phenotype; Young Adult | 2021 |
Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?
Topics: Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Breast Neoplasms; Cyclophosphamide; Drug Interactions; Female; Humans; Morpholines; Neurokinin-1 Receptor Antagonists | 2009 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Base Sequence; Breast Neoplasms; Cyclophosphamide; Cytochrome P-450 CYP2B6; DNA, Neoplasm; Female; Gene Frequency; Genotype; Humans; Introns; Japan; Lymphoma; Male; Middle Aged; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic | 2007 |
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Topics: Adolescent; Adult; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aryl Hydrocarbon Hydroxylases; Base Sequence; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Genetic; Retinal Dehydrogenase | 2008 |
Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography.
Topics: Breast Neoplasms; Chromatography, Liquid; Cyclophosphamide; Female; Humans; Hydrazones; Indicators and Reagents; Phosphoramide Mustards; Specimen Handling; Spectrophotometry, Ultraviolet; Temperature | 1994 |
Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Half-Life; Humans; Middle Aged | 1996 |
Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Female; Humans; Liver Neoplasms; Middle Aged; Nonlinear Dynamics; Phosphoramide Mustards; Thiotepa | 1997 |
Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cell Survival; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Mechlorethamine; Melphalan; Mice; Neoplasms, Experimental; Tumor Cells, Cultured | 2000 |
Novobiocin in combination with high-dose chemotherapy for the treatment of advanced breast cancer: a phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Middle Aged; Novobiocin; Survival Analysis; Thiotepa; Treatment Failure; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Breast cancer survival and in vitro tumor response in the extreme drug resistance assay.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Predictive Value of Tests; Survival Analysis | 2001 |
The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients.
Topics: Breast Neoplasms; Cell Survival; Cyclophosphamide; DNA; DNA Damage; DNA Repair; Gamma Rays; Humans; Interferon-gamma; Leukocytes, Mononuclear; Plant Extracts; Viscum album | 2002 |